Institutional
Foresite Capital Management IV, LLC
CIK 0001704132
$237.1M
Reported AUM
8
Positions
Q1 2026
Period
2026-05-15
Filed
The Brief · Foresite Capital Management IV, LLC · Q1 2026
AI · grounded in 13F
Foresite Capital Management IV, LLC established a new position in Eikon Therapeutics, Inc. EIKN valued at $20.56M. The fund also increased its stake in CYTOKINETICS INC CYTK by 9.82%. Conversely, the fund trimmed its holding in Maze Therapeutics, Inc. MAZE by 69.98%.
Portfolio · Q1 2026
Top holdings
| # | Stock | Issuer | Price | Day % | 1Y Gr. | 5Y Gr. | Value | % of book | Δ shares (QoQ) | Status |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PHVS | Pharvaris N.V. | $32.82 | -3.13% | 63.35% | 61.81% | $135.0M | 56.94% | — | HELD |
| 2 | CYTK | CYTOKINETICS INC | $78.24 | -2.71% | 118.34% | 142.98% | $33.2M | 13.99% | — | HELD |
| 3 | EIKN | Eikon Therapeutics, Inc. | $9.12 | -5.20% | -33.66% | -9.07% | $20.6M | 8.67% | — | HELD |
| 4 | LYEL | Lyell Immunopharma, Inc. | $13.06 | -4.85% | 24.50% | -95.66% | $16.1M | 6.77% | — | HELD |
| 5 | RLAY | Relay Therapeutics, Inc. | $18.71 | -3.80% | 453.27% | -41.96% | $9.9M | 4.20% | — | HELD |
| 6 | XENE | Xenon Pharmaceuticals Inc. | $62.97 | -1.89% | 110.46% | 263.68% | $9.3M | 3.92% | — | HELD |
| 7 | ALEC | Alector, Inc. | $1.55 | -4.01% | 13.45% | -93.91% | $8.4M | 3.53% | — | HELD |
| 8 | MAZE | Maze Therapeutics, Inc. | $26.58 | -3.78% | 85.44% | 125.92% | $4.7M | 1.98% | — | HELD |
Source: SEC EDGAR · accession 0001104659-26-062462. 13F discloses long positions only — shorts, foreign equities, and options are excluded.